StockNews.AI
JAGX
StockNews.AI
104 days

Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts

1. Jaguar Health outlines potential catalysts for crofelemer in 2025. 2. Crofelemer is uniquely FDA-approved under Botanical Guidance.

2m saved
Insight
Article

FAQ

Why Bullish?

Positive catalysts for crofelemer's indications could increase JAGX's market perception similar to past pharmaceutical approvals.

How important is it?

The article highlights critical upcoming developments for crofelemer, potentially driving investor interest.

Why Long Term?

The catalysts mentioned could take time to materialize, impacting JAGX's performance in subsequent quarters.

Related Companies

JNJMRKAMGN
Crofelemer is the only oral drug approved by the FDA's Center for Drug Evaluation and Research under Botanical Guidance Click here to access replay of company's April 30, 2025 investor webcast SAN FRANCISCO, CA / ACCESS Newswire / May 7, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today provided an overview of expected Q2 - Q4 2025 catalysts related to potential follow-on indications for crofelemer, the company's novel plant-based prescription drug approved by the U.S. Food and Drug Administration's Center for Drug Evaluation and Research (CDER). "As discussed during Jaguar's investor webcast last week, 2025 is a year of catalysts for crofelemer in both of our major development programs - our rare disease intestinal failure program and our cancer therapy-related diarrhea program," said Lisa Conte, Jaguar's Founder and CEO.

Related News